SK-ES-1 is a human Ewing sarcoma (anaplastic osteosarcoma) cell line that displays epithelial morphology and grows in adherent tissue culture. These cells are a useful preclinical model to study Ewing sarcoma and have been used in the assessment of experimental therapeutic agents. SK-ES-1 cells form xenograft small-cell malignant tumors consistent with Ewing sarcoma when injected into immunocompromised mice. These cells have been reported to express mutant p53 (C176F) protein.
This cell line was established in 1971 from a bone biopsy in an 18-year-old Caucasian male with Ewing’s sarcoma.
Eda T. Bloom, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Bloom ET (1972) Further definition by cytotoxicity tests of cell surface antigens of human sarcomas in culture. Cancer Research 32: 960-967 (PubMed ID: 4502173)
- Komuro H et al. (1993) Mutations of the p53 gene are involved in Ewing’s sarcomas but not in neuroblastomas. Cancer Research 53: 5284-5288 (PubMed ID: 8221663)
- McCarty G, Awad O, and Loeb DM. (2011) WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. Journal of Biological Chemistry 286: 43634-43643 (PubMed ID: 22030397)
- Sémiond D et al. (2013) Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel. Cancer Chemotherapy and Pharmacology 72: 515-528 (PubMed ID: 23820961)
This cell line may be licensed nonexclusively for research or commercial purposes.
- For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078, firstname.lastname@example.org
- For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, email@example.com